Third Harmonic Bio — Investor Presentation (March 2025)
30 slides from Third Harmonic Bio's investor presentation, Mar 11, 2025
Slide 1: Focused on advancing the next wave of medicine for inflammatory diseases
FOCUSED On advancing the next wave of medicine for inflammatory diseases MA R C H 2 0 2 5 ©2025 THIRD HARMONIC BIO
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. Any statements made in this presentation that are not statements of historical fact, inclu
Slide 3: Focused on KIT to Treat Mast Cell-Mediated Inflammatory Diseases
THRD: Focused on KIT to Treat Mast Cell-Mediated Inflammatory Diseases LARGE MARKETS ESTABLISHED WITH HIGH CLINICALLY KIT: A NOVEL, VALIDATED “PIPELINE-IN-A-TARGET” UNMET NEED TARGET CLINICAL THB335 CANDIDATE: POTENTIAL Millions of patients living Clinical validation of KIT Highly selective, oral sm
Slide 4: High Disease Burden in Chronic Spontaneous Urticaria
High Disease Burden in Chronic Spontaneous Urticaria A severe, yet undertreated dermal inflammatory condition “Out there, it’s a horrible world for urticaria patients“1 Prevalence: More than 1.5 million patients or 0.5-1% point prevalence; ~70-80% female, mean age ~46 years Disease impact: CSU sever
Slide 5: KIT is the Master Regulator of Mast Cell Function and Survival
KIT is the Master Regulator of Mast Cell Function and Survival Oral small molecule approach to KIT offers multiple potential therapeutic advantages KIT Targeting mast cell vs specific activating pathways or downstream mediators provides broad approach to addressing disease symptoms Emerging clinical
Slide 6: THB335: A Next-Generation, Potent, and Highly Selective Wild-Type KIT Inhibitor
THB335: A Next-Generation, Potent, and Highly Selective Wild-Type KIT Inhibitor THB335 Product Profile Low nanomolar KIT potency with excellent kinome selectivity in biochemical and cell-based assays Peripherally restricted biodistribution Structural and metabolic improvements vs THB001 to address D
Slide 7: In Vitro Pharmacology Overview
THB335 In Vitro Pharmacology Overview Potent, selective, reversible KIT kinase inhibitor DiscoverX KinomeSCAN @ 1 M 0% 0.1% 0.1-1% 1-5% 5-10% 10-35% > 35% Percent Control BIOCHEMICAL CELLULAR Kinase KD HTRF KIT Multiple Target (nM) IC50 (nM) (nM) KIT 1.5 16.1 5.01 – 7.92 CSF1R 33 56 >30003 – >100002
Slide 8: Phase 1 SAD/MAD/Food Effect in Healthy Volunteers
THB335: Phase 1 SAD/MAD/Food Effect in Healthy Volunteers Phase 1 Trial Design Single Ascending Dose (n=40) Multiple Ascending Dose (n=32) (fasted unless otherwise specified) 5 Healthy Male/Female, 18-65 yrs 4 205 mg Healthy Male/Female 18-65 yrs 4 Plasma PK Plasma/Urine PK Serum Tryptase 3 164 mg S
Slide 9: MAD Baseline Characteristics
THB335 MAD Baseline Characteristics DOSE 21 mg 41 mg 82 mg 164 mg Placebo Variable N=6 N=6 N=6 N=6 N=8 Sex, n (%) Female 6 (100%) 3 (50%) 6 (100%) 6 (100%) 8 (100%) Male 0 (0%) 3 (50%) 0 (0%) 0 (0%) 0 (0%) Age (years) Median 55.5 51.5 58.0 56.0 53.0 Race, n (%) White 6 (100.0%) 5 (83.3%) 6 (100.0%)
Slide 10: MAD Pharmacokinetics Summary
THB335 MAD Pharmacokinetics Summary THB335 MAD PK 21 mg Dose KIT IC90 Coverage 41 mg 82 mg Placebo (n=8) na 164 mg (ng/mL) 21 mg (n=6) ~0.5x IC90 41 mg (n=6) ~2x concentration 82 mg (n=6) ~4.5x plasma 164 mg (n=5)1 ~6.8x THB335 IC50 T1/2 ~40 hours Mild positive food effect 41% variability coefficien
Slide 11: MAD Pharmacodynamics Summary – Serum Tryptase
THB335 MAD Pharmacodynamics Summary – Serum Tryptase THB335 MAD Serum Tryptase Serum Tryptase Dose Mean % Reduction at Day 15 Placebo (n=8) 0.8% baseline) 21 mg (n=6) -13% Tryptase from 41 mg (n=6) -50% change 82 mg (n=6) -59% concentrations 164 mg (n=5)1 -84% (percent Avg (ng/mL) Visit day Placebo
Slide 12: MAD Pharmacodynamics Summary – Stem Cell Factor
THB335 MAD Pharmacodynamics Summary – Stem Cell Factor THB335 MAD Stem Cell Factor Stem Cell Factor Dose Mean % Increase at Day 16 Baseline Placebo (n=8) 0.4% from 21 mg (n=6) 9% 41 mg (n=6) 23% Change 82 mg (n=6) 43% Percent 164 mg (n=5)1 56% Mean/SD Visit day Placebo 21 mg 41 mg 82 mg 164 mg 1 One
Slide 13: MAD Safety Summary
THB335 MAD Safety Summary Adverse events reported ? 2 subjects DOSE AE TERM 21 mg 41 mg 82 mg 164 mg Placebo Hair 0 0 3 4 0 Depigmentation Low Hemoglobin 0 0 2 5 0 Decreased WBC 0 1 1 2 0 Low ANC 0 1 0 2 0 Elevated Liver 0 0 0 1 2 Enzymes Headache 0 1 0 0 1 Contact Dermatitis 1 0 0 0 1 due to EKG le
Slide 14: MAD Safety: ALT/AST Elevations
THB335 MAD Safety: ALT/AST Elevations Mild/moderate, asymptomatic and transient transaminase elevations in 3 subjects (2 placebo, 1 active) ALT (U/L) AST (U/L) ALT >500 U/L is 164 mg cohort AEs are largely consistent in international standard time course and similar in magnitude for evidence of drug
Slide 15: MAD Safety: Neutrophils (ANC)
THB335 MAD Safety: Neutrophils (ANC) Neutrophils (absolute) ANC (109/L) ULN ULN Expected on-target dose-dependent value Placebo reductions in ANC 21 mg Mean 41 mg All values normalized by follow-up 82 mg day 38 164 mg LLN Visit day 15
Slide 16: MAD Safety: Hemoglobin
THB335 MAD Safety: Hemoglobin Hemoglobin (g/dL) ULN ULN Evidence of phlebotomy effect in Placebo 21 mg decreased hemoglobin in placebo value 41 mg subjects LLN Mean 82 mg Lower baseline values 164 mg 164 mg cohorts may contribute to AE severity LLN Visit day 16
Slide 17: MAD Hematology Safety Summary
THB335 MAD Hematology Safety Summary DOSE AE TERM Severity 21 mg 41 mg 82 mg 164 mg Low hemoglobin Mild 0 0 0 0 Moderate 0 0 2 2 Severe 0 0 0 3 Low ANC Mild 0 0 0 0 Moderate 0 1 0 1 Severe 0 0 0 1 Low WBC Mild 0 1 1 1 Moderate 0 0 0 1 Severe 0 0 0 0 Hemoglobin AEs graded utilizing FDA preventative v
Slide 18: Majority female study population drives lower baseline hemoglobin values
Majority female study population drives lower baseline/day 1 values Hemoglobin values nadir at day 22, evidence of partial recovery by day 29 AE grading per FDA vaccine guidance (change from baseline) o Grade 2 (moderate): 1.6-2.0 g/dL o Grade 3 (severe): 2.1-5.0 g/dL 1 One subject discontinued at d
Slide 19: Phase 1 Clinical Trial Results Summary
THB335 Phase 1 Clinical Trial Results Summary Once daily dosing with dose-dependent increases in exposure exceeding the KIT IC90 at doses > 41mg Sustained, dose-dependent decreases in serum tryptase Safety profile which supports evaluation of moderate KIT inhibition therapeutic index optimization hy
Slide 20: "Pipeline-in-a-Target" Potential with KIT Inhibition
“Pipeline-in-a-Target” Potential with KIT Inhibition Select Mast Cell-Mediated Diseases In addition to CSU, opportunity to pursue additional mast-cell mediated inflammatory disorders – Meaningful opportunity in severe asthma, where mast cells play a central role in pathophysiology and clear need exi
Slide 21: Summary and Next Steps
Summary and Next Steps Advancing THB335 toward Phase 2 trial in CSU and strategic review process underway Advancing THB335 toward Phase 2 readiness by mid-year 2025 Launched strategic review process to identify opportunities to maximize shareholder value Implemented restructuring to halt all non-THB
Slide 22: Appendix: Previously Presented Data
APPENDIX Previously Presented Data 22
Slide 23: First-Generation THB001 Phase 1b CINDU Study Overview
First-Generation THB001 Phase 1b CINDU1 Study Overview Discontinued dose escalation study designed to interrogate potential for therapeutic index optimization DESIGN AND OBJECTIVES 3 doses (1:1:1) of THB001 (total N=30) for 12 weeks Pharmacokinetics and serum tryptase levels Mean reduction in critic
Slide 24: Early Clinical Proof-Of-Concept Demonstrated With THB001
Early Clinical Proof-Of-Concept Demonstrated With THB001 Discontinued cold inducible urticaria study results THB001 MEAN TEMPTEST AND SERUM TRYPTASE1 TempTest (°Celsius) Serum Tryptase (µg/L) 30 6 25 5 20 4 15 3 10 2 5 1 Complete LLOQ response Baseline Week 1 Week 2 Week 4 Week 6 Week 8 Week 10 Week
Slide 25: THB001 Phase 1b CINDU Study Efficacy Summary
First-Generation THB001 Phase 1b CINDU Study Efficacy Summary 4 of 5 subjects reached partial (n=2) or complete (n=2) responses at lowest planned dose of 200mg BID SUBJECT 1 >> SUBJECT 2>> SUBJECT 3>> SUBJECT 4 >> SUBJECT 5 >> PARTIAL RESPONSE PARTIAL RESPONSE NO RESPONSE COMPLETE RESPONSE COMPLETE
Slide 26: THB001 Phase 1b CINDU Study Safety Summary
First-Generation THB001 Phase 1b CINDU Study Safety Summary No serious or severe AEs Two moderate AEs of transaminitis which resolved at weeks 17 and 25 of follow-up All other AEs were mild – Overall profile consistent with on-target effects of KIT inhibition observed in the Phase 1a study (e.g., ha
Slide 27: THB001 Showed Evidence of Reactive Metabolite Formation
THB001 Showed Evidence of Reactive Metabolite Formation Mechanistic studies provide potential basis for observed transaminitis [14C] THB001 COVALENT PROTEIN ADDUCT FORMATION IN HUMAN LIVER MICROSOMES IS REDUCED IN THE PRESENCE OF GSH OR CYP INHIBITION THB001 Reactive metabolite “Detoxification” path
Slide 28: THB335 is Metabolically Distinct from THB001
THB335 is Metabolically Distinct from THB001 Next-generation structural modifications functionally block the site of reactive metabolite formation Diol formed via a reactive epoxide identified as major metabolite of THB001 – GSH adduct formation associated with detoxification pathways Next-generatio
Slide 29: Next-Gen is Phenotypically Distinct from THB001 in Human Hepatocyte Culture
Next-Gen is Phenotypically Distinct from THB001 in Human Hepatocyte Culture No evidence for induction of oxidative stress pathways with next-generation analog of THB335 SPHEROID MODEL Primary human hepatocytes co-cultured with Kupffer and endothelial cells to replicate physiologic liver functions (e
Slide 30: Third Harmonic Bio
Third Harmonic Bio 30
Third Harmonic Bio — Investor Presentation (March 2025) on 6ix